Logo

Bluebird Bio and Gritstone Oncology signs a Research Collaboration

Share this

Bluebird Bio and Gritstone Oncology signs a Research Collaboration

Shots:
  •  Bluebird and Gritstone collaborated to research- develop and commercialize products to treat multiple cancer using cell therapies. Gritstone will provide 10 tumor-specific targets and T-cell receptors (TCRs) in certain cases
  •  Bluebird bio will take care of development- manufacturing and commercial activities. Gritstone will utilize its technology platform to enable patient selection for clinical studies
  •  Gritstone to receive $20M upfront and additional $10M Series C equity investment from Bluebird. Gritstone is also eligible for development- regulatory and commercial milestones payments on any therapies- and royalties on certain approved therapies
/ | Ref: Bluebirdbio | Image: Business Wire

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions